New and Shorter regimen for drug resistant TB
Key Questions Answered
Q1. What is the BPaLM regimen?
BPaLM is a newer shorter all-oral treatment regimen for drug-resistant TB consisting of:
B – Bedaquiline
Pa – Pretomanid
L – Linezolid
M – Moxifloxacin
It is used mainly for:
MDR-TB,
Rifampicin-resistant TB,
and certain pre-XDR TB cases.
Q2. Why is BPaLM considered a major breakthrough in DR-TB care?
Traditional DR-TB treatment:
lasted 18–24 months,
required painful injectables,
caused severe side effects,
and had poor adherence.
BPaLM offers:
*shorter duration (~6 months)
*fully oral treatment
*better convenience
*improved adherence
*promising success rates
Q3. What are the major advantages of BPaLM?
*Shorter treatment duration
*Reduces treatment fatigue.
*No injectable drugs
*Avoids hearing loss and injection-related complications.
*Better adherence
*Simpler regimens improve treatment completion.
*Improved quality of life
*Patients can continue routine activities more easily.
*Reduced hospitalization burden
*Less prolonged hospital stay may be required.
Q4. Why does India need cautious implementation of BPaLM?
India has one of the world’s highest DR-TB burdens, widespread antibiotic misuse,
and rising Fluoroquinolone resistance. Therefore:
drug stewardship becomes critically important.
Q5. What are the major concerns regarding BPaLM?
*Linezolid toxicity- may cause peripheral neuropathy, optic neuropathy, bone marrow suppression.Fluoroquinolone resistanc – Moxifloxacin belongs to Fluoroquinolones. India already faces significant resistance due to irrational antibiotic use.
*Dependence on limited newer drugs – Bedaquiline and Pretomanid are precious anti-TB drugs.
Misuse may threaten future effectiveness.
*Risk of future resistance amplification – Poor adherence may lead to resistance against newer drugs.
*Programme
implementation challenges
Requires:
strong DST systems,
pharmacovigilance,
trained workforce,
adverse-event monitoring,
and strict follow-up.
Q6. Can shorter regimens alone eliminate DR-TB?
No.
DR-TB is also driven by:
delayed diagnosis,
treatment interruption,
irrational antibiotic use,
undernutrition, tobacco use, diabetes,
and poor adherence.
Q7. Why is antibiotic stewardship important in TB?
New TB drugs are limited national and global resources. Irrational or uncontrolled use may reduce future effectiveness.
Every breakthrough regimen must be protected through responsible use.
Q8. What should India focus on while expanding BPaLM?
India should strengthen:
*Universal DST
*Pharmacovigilance
*Adherence support
*Rational antibiotic use
*Nutrition support
*Tobacco control
*Diabetes management
Q9. What is the key public-health message regarding BPaLM?
Innovation gives us new drugs → Stewardship protects their future
*Conclusion*Dr. S.K. Arora states that new TB drugs are limited resources, and their future is secured only through responsible usage. Along with these new drugs, attention must also be paid to other causes behind DR-TB, such as delayed diagnosis, incomplete treatment, misuse of antibiotics, malnutrition, tobacco use, diabetes, and poor adherence.
While shorter treatment is a remarkable scientific achievement, preserving the efficacy of these drugs remains a core public health issue.
Dr. S.K. Arora
Senior Chest Specialist & Consultant, Former Delhi State TB Head, Government of Delhi (WHO Awardee)
TB Expert | Tobacco Control Advocate | Public Health (India)
